Company profile
PLIANT THERAPEUTICS, INC.
NASDAQ:PLRXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BEXOTEGRAST | phase2 | — | 6 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06270706 | phase1 | recruiting | 2023-08-30 | 2030-06-01 | Pliant Therapeutics, Inc. | A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors |
| NCT04396756 | phase2 | completed | 2020-03-03 | 2023-02-01 | Pliant Therapeutics, Inc. | Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis |
| NCT04565249 | phase2 | terminated | 2020-10-22 | 2021-06-01 | Pliant Therapeutics, Inc. | Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19 |
| NCT05621252 | phase2 | completed | 2022-07-13 | 2023-12-27 | Pliant Therapeutics, Inc. | Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809) |
| NCT04072315 | phase2 | completed | 2020-02-13 | 2022-06-27 | Pliant Therapeutics, Inc. | Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/ |
FDA applications (0)
No records yet.